This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
COO Q2 Earnings Signal Growth and Caution: How to Play the Stock?
by Zacks Equity Research
Cooper Companies beats fiscal second-quarter estimates and raises guidance, but faces fertility headwinds and inventory pressures. Is COO still a long-term growth play?
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
by Zacks Equity Research
ORIC Pharmaceuticals stock rises 20% pre-market on early data showing strong PSA responses and tolerability for prostate cancer drug ORIC-944 in phase Ib study.
Johnson & Johnson (JNJ) Stock Moves -0.54%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $152.43, denoting a -0.54% change from the preceding trading day.
TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?
by Kinjel Shah
TEVA rises 12.9% in a month as investors react to mixed first-quarter results, cost-cutting plans and growing momentum in branded and biosimilar drug sales.
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for HDV
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $152.51, denoting a -0.44% change from the preceding trading day.
JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges
by Kinjel Shah
While J&J's Innovative Medicines segment is showing a growth trend, the MedTech unit's slowdown is a concern
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
by Zacks Equity Research
CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes Linger
by Kinjel Shah
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Johnson & Johnson (JNJ) Down 4.9% Since Last Earnings Report?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ISRG Stock Gains More than 8% YTD: Will the Uptrend Continue?
by Indrajit Bandyopadhyay
Intuitive Surgical's shares seem to recover after declining more than 30% in nearly two months. Is it the right time to invest?
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Hurts Sales
by Zacks Equity Research
BAYRY's first-quarter earnings beat expectations. Revenues miss estimates, mainly due to lower sales of its products in the Crop Science division.
The Zacks Analyst Blog Highlights J&J, Eli Lilly, Pfizer, Merck, Amgen
by Zacks Equity Research
J&J, Eli Lilly, Pfizer, Merck, Amgen are included in this Analyst Blog.
RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US
by Zacks Equity Research
Roche plans to invest over $700 million in setting up a new plant in North Carolina and up to $550 million in expanding its Indianapolis diagnostics hub.
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
by Kinjel Shah
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with JNJ's icotrokinra helps achieve significant skin clearance in hard-to-treat scalp and genital psoriasis.
Is Invesco S&P 500 Quality ETF (SPHQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SPHQ
A Look at Pharma ETFs After Strong Q1 Earnings
by Sweta Killa
Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.
TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up
by Zacks Equity Research
TEVA shares rise despite mixed first-quarter results. Teva lowers the higher end of its 2025 sales guidance while increasing the lower end of its EPS range.
HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View
by Zacks Equity Research
Halozyme reports better-than-expected first-quarter 2025 results. The company increases revenue guidance for 2025. Shares rise.
The Zacks Analyst Blog Highlights Johnson & Johnson and AbbVie
by Zacks Equity Research
Johnson & Johnson and AbbVie are part of the Zacks top Analyst Blog.